Looks like you’re on the UK site. Choose another location to see content specific to your location
Boehringer Ingelheim and Servier agree manufacturing deal
Boehringer Ingelheim has agreed a manufacturing deal with Servier and its partner Xoma regarding production of the novel antibody gevokizumab.
Under the terms of the agreement, Xoma's technology and process for the commercial manufacture of the novel interleukin 1-beta allosteric modulating antibody will be transferred to Boehringer Ingelheim.
The compound in question is currently in phase III clinical development among patients with non-infectious uveitis, with Boehringer Ingelheim to manufacture the drug in Germany for Servier's commercial use.
Boehringer Ingelheim was picked on the strength of its track record of successful technology transfers, as well as its ability to produce materials in both Europe and the US.
Simon Sturge, corporate senior vice-president for biopharmaceuticals at Boehringer Ingelheim, said: "We look forward to leveraging our more than 35 years expertise in this area to support both companies in further executing their clinical development strategies for gevokizumab."
In June 2012, the company launched the new BioXcellence brand identity for its biopharmaceutical contract manufacturing business.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard